PTC Therapeutics, Inc. (PTCT) financial statements (2021 and earlier)

Company profile

Business Address 100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080-2449
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments687709364407228249296
Cash and cash equivalents288524136201169207224
Short-term investments399185227206584272
Receivables56607746684259
Inventory, net of allowances, customer advances and progress billings19171716161414
Inventory19171716161414
Other undisclosed current assets1821179986
Total current assets:779807475479321313376
Noncurrent Assets
Operating lease, right-of-use asset141410 
Property, plant and equipment221815151398
Intangible assets, net (including goodwill)793785785777783705126
Goodwill8282828282100 
Intangible assets, net (excluding goodwill)711703703695701605126
Other undisclosed noncurrent assets1617613222
Total noncurrent assets:844835817805798715136
TOTAL ASSETS:1,6241,6411,2921,2841,1191,029512
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1591281229812810383
Accounts payable1091010674
Accrued liabilities132015922169
Employee-related liabilities39261913281813
Other undisclosed accounts payable and accrued liabilities97737967736256
Deferred revenue898 
Debt252522171272
Contract with customer, liability542 
Other liabilities8743432
Other undisclosed current liabilities3515171919  
Total current liabilities:23618417414316711586
Noncurrent Liabilities
Long-term debt and lease obligation294303144138141144147
Long-term debt, excluding current maturities294293136138141144147
Operating lease, liability 98 
Liabilities, other than long-term debt50036035247144234511
Deferred revenue358 
Contract with customer, liability9101111
Deferred tax liabilities, net122122115 
Deferred income tax liabilities131   
Other liabilities9989000
Business combination, contingent consideration, liability356345336331310219 
Other undisclosed noncurrent liabilities 132132191838 
Total noncurrent liabilities:794794629628602528158
Total liabilities:1,029978803771768643244
Stockholders' equity
Stockholders' equity attributable to parent594664489513351386267
Common stock0000000
Additional paid in capital1,7951,7761,5401,5231,2881,2751,105
Accumulated other comprehensive income (loss)(11)121122
Accumulated deficit(1,190)(1,113)(1,053)(1,011)(939)(891)(840)
Total stockholders' equity:594664489513351386267
TOTAL LIABILITIES AND EQUITY:1,6241,6411,2921,2841,1191,029512

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues96718654865469
Cost of revenue
(Cost of Goods and Services Sold)
(4)(3)(3)(2)7(3)(3)
Gross profit:93688251935066
Operating expenses(169)(132)(124)(123)(131)(102)(74)
Other undisclosed operating income (loss)4332(7)33
Operating loss:(73)(60)(39)(69)(45)(48)(6)
Nonoperating income (expense)233(0)(0)(1)1(1)
Foreign currency transaction gain, before tax12   0  
Other nonoperating income (expense)113(0)(0)(1)1(1)
Interest and debt expense(0)  (0)(0)  
Other undisclosed loss from continuing operations before equity method investments, income taxes(23)   (12)  
Loss from continuing operations before equity method investments, income taxes:(74)(58)(39)(69)(58)(47)(6)
Other undisclosed income (loss) from continuing operations before income taxes7(3)(2)(2)9(3)(3)
Loss from continuing operations before income taxes:(67)(60)(41)(72)(49)(51)(9)
Income tax expense (benefit)(11)0(1)11(0)(0)
Net loss:(78)(60)(42)(71)(48)(51)(10)
Other undisclosed net loss attributable to parent   (1)   
Net loss available to common stockholders, diluted:(78)(60)(42)(72)(48)(51)(10)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(78)(60)(42)(71)(48)(51)(10)
Other comprehensive income (loss)(11)(1)1(1)(0)(0)(3)
Comprehensive loss:(89)(61)(41)(72)(48)(51)(13)
Other undisclosed comprehensive loss, net of tax, attributable to parent   (1)   
Comprehensive loss, net of tax, attributable to parent:(89)(61)(41)(73)(48)(51)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: